Woman becomes first to receive pioneering new cancer therapy

Namir Hassan, chief executive of Norwegian firm Zelluna, which makes ZI-MA4-1, said Mrs Tomlinson’s first dose is a “landmark moment”, adding: “It represents the moment when years of research moved beyond the laboratory and into the clinic, offering a new potential treatment option for patients facing advanced cancers with limited alternatives.”